Edwin Liu
Concepts (362)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 67 | 2026 | 285 | 11.440 |
Why?
| | Autoantibodies | 49 | 2026 | 1498 | 3.040 |
Why?
| | Transglutaminases | 28 | 2025 | 137 | 2.930 |
Why?
| | Diet, Gluten-Free | 15 | 2026 | 56 | 2.470 |
Why?
| | Glutens | 11 | 2026 | 57 | 1.870 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 171 | 1.830 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 466 | 1.500 |
Why?
| | Autoimmunity | 23 | 2024 | 924 | 1.440 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 150 | 1.340 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3930 | 1.300 |
Why?
| | Peptide Fragments | 15 | 2008 | 693 | 1.190 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2455 | 1.190 |
Why?
| | Insulin | 24 | 2009 | 2524 | 1.150 |
Why?
| | Food Contamination | 1 | 2026 | 36 | 0.970 |
Why?
| | Fast Foods | 1 | 2026 | 24 | 0.970 |
Why?
| | Cooking | 1 | 2026 | 62 | 0.940 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 76 | 0.860 |
Why?
| | Islets of Langerhans | 17 | 2017 | 852 | 0.810 |
Why?
| | Rett Syndrome | 1 | 2024 | 44 | 0.800 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 211 | 0.720 |
Why?
| | Insulin Antibodies | 11 | 2013 | 103 | 0.710 |
Why?
| | Patient Compliance | 3 | 2026 | 587 | 0.700 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 220 | 0.700 |
Why?
| | Nutrition Therapy | 1 | 2020 | 37 | 0.620 |
Why?
| | Child | 46 | 2026 | 22638 | 0.610 |
Why?
| | Pyrrolidinones | 1 | 2019 | 29 | 0.590 |
Why?
| | Genetic Testing | 6 | 2015 | 491 | 0.590 |
Why?
| | Child, Preschool | 33 | 2026 | 11888 | 0.580 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 598 | 0.540 |
Why?
| | Nutritionists | 3 | 2026 | 24 | 0.520 |
Why?
| | Down Syndrome | 2 | 2023 | 529 | 0.510 |
Why?
| | Immunoglobulin A | 9 | 2025 | 205 | 0.500 |
Why?
| | Mass Screening | 8 | 2024 | 1300 | 0.500 |
Why?
| | Anticonvulsants | 1 | 2019 | 251 | 0.490 |
Why?
| | Humans | 90 | 2026 | 145625 | 0.470 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 198 | 0.460 |
Why?
| | Intestinal Mucosa | 5 | 2026 | 666 | 0.450 |
Why?
| | Infant | 27 | 2025 | 10093 | 0.430 |
Why?
| | Epilepsy | 1 | 2019 | 397 | 0.420 |
Why?
| | Anaphylaxis | 3 | 2004 | 105 | 0.400 |
Why?
| | Poly I-C | 4 | 2008 | 58 | 0.390 |
Why?
| | Adolescent | 26 | 2026 | 22451 | 0.380 |
Why?
| | Depression | 2 | 2022 | 1566 | 0.370 |
Why?
| | Caregivers | 1 | 2022 | 1079 | 0.370 |
Why?
| | Female | 59 | 2026 | 79080 | 0.370 |
Why?
| | Gliadin | 3 | 2018 | 11 | 0.360 |
Why?
| | Radioimmunoassay | 3 | 2016 | 162 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2228 | 0.340 |
Why?
| | Prospective Studies | 21 | 2024 | 8087 | 0.330 |
Why?
| | Male | 50 | 2026 | 73014 | 0.330 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5397 | 0.330 |
Why?
| | Jejunum | 1 | 2011 | 36 | 0.330 |
Why?
| | Telemedicine | 1 | 2020 | 956 | 0.320 |
Why?
| | Biopsy | 11 | 2025 | 1073 | 0.320 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 243 | 0.310 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.310 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1992 | 0.300 |
Why?
| | Quality of Life | 5 | 2024 | 3187 | 0.290 |
Why?
| | Luminescent Measurements | 2 | 2020 | 75 | 0.280 |
Why?
| | Risk Factors | 17 | 2024 | 10840 | 0.280 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 70 | 0.280 |
Why?
| | Dietary Proteins | 2 | 2019 | 135 | 0.270 |
Why?
| | Laboratories | 1 | 2009 | 109 | 0.270 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 3 | 0.250 |
Why?
| | Interferon-alpha | 2 | 2005 | 201 | 0.250 |
Why?
| | Mice | 32 | 2013 | 18266 | 0.250 |
Why?
| | Poly A-U | 1 | 2006 | 3 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2026 | 5875 | 0.250 |
Why?
| | Restaurants | 1 | 2026 | 25 | 0.240 |
Why?
| | Immune Tolerance | 4 | 2013 | 384 | 0.240 |
Why?
| | Europe | 6 | 2017 | 420 | 0.240 |
Why?
| | T-Lymphocytes | 7 | 2008 | 2007 | 0.240 |
Why?
| | Serologic Tests | 4 | 2021 | 50 | 0.230 |
Why?
| | Time Factors | 10 | 2025 | 7079 | 0.220 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2026 | 61 | 0.220 |
Why?
| | HLA Antigens | 5 | 2019 | 241 | 0.210 |
Why?
| | Celiac Plexus | 1 | 2024 | 7 | 0.210 |
Why?
| | Dyspepsia | 1 | 2024 | 11 | 0.210 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2097 | 0.210 |
Why?
| | United States | 11 | 2026 | 16041 | 0.210 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 845 | 0.210 |
Why?
| | CD4 Antigens | 2 | 2003 | 135 | 0.200 |
Why?
| | Antibodies | 3 | 2014 | 395 | 0.200 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 62 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Genotype | 7 | 2019 | 1866 | 0.200 |
Why?
| | Autoantigens | 6 | 2009 | 426 | 0.190 |
Why?
| | Animals | 34 | 2015 | 38030 | 0.190 |
Why?
| | Iron | 1 | 2026 | 359 | 0.190 |
Why?
| | Peptides | 3 | 2018 | 991 | 0.190 |
Why?
| | Diet | 4 | 2019 | 1271 | 0.190 |
Why?
| | Abdominal Pain | 1 | 2024 | 148 | 0.190 |
Why?
| | Endosonography | 1 | 2024 | 160 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 676 | 0.180 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1244 | 0.180 |
Why?
| | Biomarkers | 7 | 2025 | 4329 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 535 | 0.180 |
Why?
| | Ileal Diseases | 1 | 2001 | 11 | 0.170 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 24 | 0.170 |
Why?
| | Catheterization | 2 | 2001 | 178 | 0.170 |
Why?
| | Prevalence | 4 | 2026 | 2852 | 0.170 |
Why?
| | Colonic Diseases | 1 | 2001 | 36 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1652 | 0.170 |
Why?
| | Clinical Trials as Topic | 1 | 2026 | 1062 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2131 | 0.160 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1318 | 0.160 |
Why?
| | Dietetics | 1 | 2020 | 24 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 512 | 0.150 |
Why?
| | Environmental Exposure | 1 | 2024 | 578 | 0.150 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 102 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1148 | 0.150 |
Why?
| | Vaccines | 1 | 2004 | 389 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2019 | 6449 | 0.150 |
Why?
| | Incidence | 5 | 2022 | 2910 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 83 | 0.140 |
Why?
| | Immunization | 4 | 2007 | 375 | 0.140 |
Why?
| | Probiotics | 1 | 2019 | 61 | 0.140 |
Why?
| | Risk | 3 | 2019 | 917 | 0.140 |
Why?
| | Duodenum | 3 | 2023 | 76 | 0.140 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1101 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 197 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 352 | 0.130 |
Why?
| | Risk Assessment | 8 | 2020 | 3678 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1511 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2026 | 17291 | 0.130 |
Why?
| | Anxiety | 2 | 2022 | 1118 | 0.120 |
Why?
| | Parents | 2 | 2024 | 1393 | 0.120 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 16 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 48 | 0.120 |
Why?
| | Feces | 1 | 2019 | 494 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 175 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 63 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 82 | 0.120 |
Why?
| | Cesarean Section | 1 | 2018 | 229 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6050 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2020 | 769 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4565 | 0.110 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3396 | 0.110 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 88 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 74 | 0.100 |
Why?
| | Immunoglobulin G | 3 | 2021 | 899 | 0.100 |
Why?
| | Case-Control Studies | 6 | 2019 | 3633 | 0.100 |
Why?
| | Homozygote | 1 | 2014 | 196 | 0.100 |
Why?
| | Weight Gain | 1 | 2017 | 561 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 427 | 0.100 |
Why?
| | ROC Curve | 3 | 2013 | 613 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 192 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 3121 | 0.090 |
Why?
| | Clonal Anergy | 1 | 2013 | 55 | 0.090 |
Why?
| | Child Development | 1 | 2017 | 481 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Mice, SCID | 4 | 2008 | 360 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 161 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2088 | 0.090 |
Why?
| | Cohort Studies | 6 | 2025 | 6045 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 78 | 0.090 |
Why?
| | Young Adult | 5 | 2024 | 14240 | 0.090 |
Why?
| | Protein Precursors | 2 | 2003 | 127 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 54 | 0.090 |
Why?
| | Sweden | 3 | 2017 | 114 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 959 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 492 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 447 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1101 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4588 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 310 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2024 | 11744 | 0.080 |
Why?
| | Adenoviridae | 2 | 2019 | 196 | 0.080 |
Why?
| | Proinsulin | 3 | 2008 | 54 | 0.080 |
Why?
| | Plant Proteins | 1 | 2011 | 110 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1935 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 315 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 32 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 691 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 929 | 0.070 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 6021 | 0.070 |
Why?
| | Radioligand Assay | 1 | 2009 | 34 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1403 | 0.070 |
Why?
| | Ammonia | 2 | 2008 | 61 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 25 | 0.070 |
Why?
| | Bilirubin | 2 | 2008 | 101 | 0.070 |
Why?
| | Prediabetic State | 3 | 2009 | 250 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2910 | 0.070 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 10 | 0.070 |
Why?
| | Dietary Supplements | 2 | 2026 | 586 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 170 | 0.070 |
Why?
| | Decision Support Techniques | 1 | 2013 | 473 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 503 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 182 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2857 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 381 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 27 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 55 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 102 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2020 | 339 | 0.060 |
Why?
| | Self-Help Groups | 1 | 2007 | 33 | 0.060 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 208 | 0.060 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 11 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 780 | 0.060 |
Why?
| | Adult | 8 | 2023 | 40821 | 0.060 |
Why?
| | Blood Glucose | 3 | 2006 | 2357 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 120 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 290 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 290 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2112 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 42 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2018 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 160 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2026 | 207 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1122 | 0.050 |
Why?
| | Age Factors | 3 | 2017 | 3321 | 0.050 |
Why?
| | Isoelectric Point | 1 | 2004 | 21 | 0.050 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 10 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 12 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 112 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2835 | 0.050 |
Why?
| | Survival Rate | 2 | 2007 | 2078 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 97 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 884 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 64 | 0.050 |
Why?
| | Canada | 1 | 2025 | 430 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 337 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 185 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 188 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 533 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 479 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 275 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 113 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 163 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 21 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 6 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 31 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1500 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2591 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 38 | 0.040 |
Why?
| | Thyroid Diseases | 1 | 2002 | 45 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 365 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2004 | 887 | 0.040 |
Why?
| | Oligopeptides | 1 | 2003 | 264 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 69 | 0.040 |
Why?
| | Paracentesis | 1 | 2001 | 16 | 0.040 |
Why?
| | Immunotherapy | 1 | 2007 | 669 | 0.040 |
Why?
| | Gastroschisis | 1 | 2001 | 32 | 0.040 |
Why?
| | Ascites | 1 | 2001 | 47 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 161 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 708 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1461 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4331 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 102 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1372 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 502 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 869 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1843 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 284 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 87 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 276 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 254 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1581 | 0.030 |
Why?
| | Pilot Projects | 1 | 2024 | 1878 | 0.030 |
Why?
| | Metagenomics | 1 | 2019 | 153 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5574 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2017 | 3005 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 122 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 477 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 434 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 17 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 290 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 170 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 39 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 649 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 787 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3186 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1754 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 782 | 0.030 |
Why?
| | China | 1 | 2016 | 278 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 170 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1728 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 267 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 487 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 192 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 133 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 97 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1444 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 75 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 700 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1983 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 495 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1709 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 314 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2119 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 351 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 727 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1323 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 133 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 244 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 399 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 166 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 867 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2446 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 542 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2101 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 415 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 771 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 537 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 61 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 395 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 379 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 12 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7217 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 34 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 21 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 15 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 37 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 77 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1136 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2382 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2962 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 22 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 259 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 242 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 372 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 17 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 39 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 94 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 175 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 330 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 298 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4112 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 42 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 171 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2809 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 106 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 557 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 71 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 70 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2623 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1824 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 559 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 233 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 114 | 0.010 |
Why?
| | Needles | 1 | 2001 | 61 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 187 | 0.010 |
Why?
| | Safety | 1 | 2001 | 346 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 900 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 843 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3123 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 36359 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 4082 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|